SMi is proud to be hosting its 13th annual Clinical Trials in CNS conference on the 11th and 12th of November in London, UK.

LONDON, SELECT STATE/PROVINCE, UNITED KINGDOM, October 7, 2014 /EINPresswire.com/ -- Parkinson’s Disease is considered the second largest neurological illness in the elderly after Alzheimer’s and it is estimated that 6.3 million people have it worldwide. This neurodegenerative neurological movement disorder mostly affects people over the age of 65, however 15% of people can also develop it before the age of 50 (Source: Medtronic, 2014).

Based on this, SMi is proud to be hosting its 13th annual Clinical Trials in CNS conference on the 11th and 12th of November in London, UK. Speaking at this year’s event will be Richard Wyse, Director of Research and Development of the Cure Parkinson’s Trust. In his speech he will discuss the latest developments in Parkinson’s Disease by addressing the development of new treatments, the challenges of carrying out clinical trials in this area and how current research on this disease can translate to other neurological diseases.
Join this year’s conference to gain insight into improving your clinical trial design and outcomes.

Reasons to attend:
• Gain insight into improving clinical trial design and outcomes
• Receive updates on progress in therapeutics for major CNS disorders: Alzheimer’s, MS, Parkinson’s and Schizophrenia
• Review challenges in trial endpoint selection and understand how to overcome them
• Consider perspectives on the future of CNS research, targets and drug development
• Discuss the benefits of industry and academic partnerships

Key Speakers Include:
- Alan Palmer, Co-Founder and Director, MS Therapeutics
- Veronique Bragulat, Clinical Imaging Manager, GSK
- Sophie Dix, Senior Research Scientist, Neurodegenerative Disease Drug Hunting Team, Eli Lilly
- David Willé, Applied Statistician, GSK
- Ernst-Wilhelm Radue, CEO, MIAC AG
- Edwin Johnson, Director, Stockholm Brain Institute
- Shahid Zaman, Affiliated Lecturer, University of Cambridge

For more information please visit http://www.smi-online.co.uk/2014clinicaltrialscns19.asp

Sarah Watson
email us here
SMi Group Ltd
442078276134